207 related articles for article (PubMed ID: 4038321)
21. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
Richardson D; Ponka P; Baker E
Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
[TBL] [Abstract][Full Text] [Related]
22. Effect of desferrioxamine, rhodotorulic acid and cholylhydroxamic acid on transferrin and iron exchange with hepatocytes in culture.
Baker E; Page M; Torrance J; Grady R
Clin Physiol Biochem; 1985; 3(6):277-88. PubMed ID: 4075694
[TBL] [Abstract][Full Text] [Related]
23. The iron chelator pyridoxal isonicotinoyl hydrazone inhibits mitochondrial lipid peroxidation induced by Fe(II)-citrate.
Santos NC; Castilho RF; Meinicke AR; Hermes-Lima M
Eur J Pharmacol; 2001 Sep; 428(1):37-44. PubMed ID: 11779035
[TBL] [Abstract][Full Text] [Related]
24. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro.
Ponka P; Richardson DR; Edward JT; Chubb FL
Can J Physiol Pharmacol; 1994 Jun; 72(6):659-66. PubMed ID: 7954097
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
Hershko C; Avramovici-Grisaru S; Link G; Gelfand L; Sarel S
J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
[TBL] [Abstract][Full Text] [Related]
26. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties.
Buss JL; Neuzil J; Gellert N; Weber C; Ponka P
Biochem Pharmacol; 2003 Jan; 65(2):161-72. PubMed ID: 12504792
[TBL] [Abstract][Full Text] [Related]
27. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease.
Richardson DR; Ponka P
J Lab Clin Med; 1998 Apr; 131(4):306-15. PubMed ID: 9579383
[TBL] [Abstract][Full Text] [Related]
28. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs.
Johnson DK; Pippard MJ; Murphy TB; Rose NJ
J Pharmacol Exp Ther; 1982 May; 221(2):399-403. PubMed ID: 7077535
[TBL] [Abstract][Full Text] [Related]
29. Pyridoxal isonicotinoyl hydrazone inhibits iron-induced ascorbate oxidation and ascorbyl radical formation.
MaurĂcio AQ; Lopes GK; Gomes CS; Oliveira RG; Alonso A; Hermes-Lima M
Biochim Biophys Acta; 2003 Mar; 1620(1-3):15-24. PubMed ID: 12595068
[TBL] [Abstract][Full Text] [Related]
30. Pyridoxal isonicotinoyl hydrazone (PIH): a promising new iron chelator.
Webb J; Vitolo ML
Birth Defects Orig Artic Ser; 1988; 23(5B):63-70. PubMed ID: 3291971
[No Abstract] [Full Text] [Related]
31. Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate.
Chitambar CR; Boon P; Wereley JP
Clin Cancer Res; 1996 Jun; 2(6):1009-15. PubMed ID: 9816262
[TBL] [Abstract][Full Text] [Related]
32. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against *OH-mediated strand breaks.
Hermes-Lima M; Nagy E; Ponka P; Schulman HM
Free Radic Biol Med; 1998 Nov; 25(8):875-80. PubMed ID: 9840731
[TBL] [Abstract][Full Text] [Related]
33. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
34. The release of iron and transferrin from the human melanoma cell.
Richardson DR; Baker E
Biochim Biophys Acta; 1991 Feb; 1091(3):294-302. PubMed ID: 2001412
[TBL] [Abstract][Full Text] [Related]
35. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II).
Richardson DR; Hefter GT; May PM; Webb J; Baker E
Biol Met; 1989; 2(3):161-7. PubMed ID: 2490071
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of oral iron chelators assayed in the rat.
Kim BK; Huebers HA; Finch CA
Am J Hematol; 1987 Mar; 24(3):277-84. PubMed ID: 3826055
[TBL] [Abstract][Full Text] [Related]
37. Uptake and intracellular handling of iron from transferrin and iron chelates by mitogen stimulated mouse lymphocytes.
Djeha A; Brock JH
Biochim Biophys Acta; 1992 Jan; 1133(2):147-52. PubMed ID: 1731957
[TBL] [Abstract][Full Text] [Related]
38. Aging-related changes in the iron status of skeletal muscle.
DeRuisseau KC; Park YM; DeRuisseau LR; Cowley PM; Fazen CH; Doyle RP
Exp Gerontol; 2013 Nov; 48(11):1294-302. PubMed ID: 23994517
[TBL] [Abstract][Full Text] [Related]
39. The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron.
Chen YL; Kong X; Xie Y; Hider RC
J Inorg Biochem; 2018 Mar; 180():194-203. PubMed ID: 29329026
[TBL] [Abstract][Full Text] [Related]
40. Pyridoxal isonicotinoyl hydrazone and its analogues.
Buss JL; Hermes-Lima M; Ponka P
Adv Exp Med Biol; 2002; 509():205-29. PubMed ID: 12572996
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]